- Home
- HNRG vs AKBA Comparison
HNRG vs AKBA Comparison
Compare HNRG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- AKBA
- Stock Information
- Founded
- HNRG 1949
- AKBA 2007
- Country
- HNRG United States
- AKBA United States
- Employees
- HNRG N/A
- AKBA N/A
- Industry
- HNRG Coal Mining
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- AKBA Health Care
- Exchange
- HNRG Nasdaq
- AKBA Nasdaq
- Market Cap
- HNRG 823.6M
- AKBA 729.1M
- IPO Year
- HNRG N/A
- AKBA 2014
- Fundamental
- Price
- HNRG $20.77
- AKBA $2.18
- Analyst Decision
- HNRG Strong Buy
- AKBA Strong Buy
- Analyst Count
- HNRG 4
- AKBA 6
- Target Price
- HNRG $20.00
- AKBA $6.25
- AVG Volume (30 Days)
- HNRG 473.7K
- AKBA 4.3M
- Earning Date
- HNRG 11-10-2025
- AKBA 11-10-2025
- Dividend Yield
- HNRG N/A
- AKBA N/A
- EPS Growth
- HNRG N/A
- AKBA N/A
- EPS
- HNRG N/A
- AKBA N/A
- Revenue
- HNRG $419,451,000.00
- AKBA $203,733,000.00
- Revenue This Year
- HNRG $11.19
- AKBA $43.91
- Revenue Next Year
- HNRG $4.79
- AKBA $32.09
- P/E Ratio
- HNRG N/A
- AKBA N/A
- Revenue Growth
- HNRG N/A
- AKBA 16.75
- 52 Week Low
- HNRG $8.13
- AKBA $1.52
- 52 Week High
- HNRG $22.44
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- HNRG 54.84
- AKBA 30.52
- Support Level
- HNRG $19.92
- AKBA $2.07
- Resistance Level
- HNRG $21.24
- AKBA $3.19
- Average True Range (ATR)
- HNRG 1.00
- AKBA 0.17
- MACD
- HNRG -0.07
- AKBA -0.09
- Stochastic Oscillator
- HNRG 45.74
- AKBA 8.93
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.